Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators

JAMA Oncology ◽

10.1001/jamaoncol.2021.3428 ◽

2021 ◽

pp. e213428

Author(s):

Ying Fan ◽

Tao Sun ◽

Zhimin Shao ◽

Qingyuan Zhang ◽

Quchang Ouyang ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Advanced Breast Cancer ◽

Disease Progression ◽

Premenopausal Women ◽

Line Treatment ◽

First Line ◽

Estrogen Receptor Modulators ◽

Receptor Modulators ◽

First Line Treatment

Download Full-text

First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis

Clinical Breast Cancer ◽

10.1016/j.clbc.2021.01.019 ◽

2021 ◽

Author(s):

Xiaoting Huang ◽

Shen Lin ◽

Xin Rao ◽

Dayong Zeng ◽

Hang Wang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Premenopausal Women ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer

10.21873/anticanres.12000 ◽

2017 ◽

Vol 37 (10) ◽

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment

Current Medical Research and Opinion ◽

10.1185/03007995.2016.1157060 ◽

2016 ◽

Vol 32 (5) ◽

pp. 959-965 ◽

Cited By ~ 11

Author(s):

T. Bell ◽

J.P. Crown ◽

I. Lang ◽

H. Bhattacharyya ◽

G. Zanotti ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Epidermal Growth Factor Receptor ◽

Growth Factor Receptor ◽

Daily Activities ◽

Line Treatment ◽

First Line ◽

Estrogen Receptor Positive ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis

Targeted Oncology ◽

10.1007/s11523-019-00633-9 ◽

2019 ◽

Vol 14 (2) ◽

pp. 139-148 ◽

Cited By ~ 5

Author(s):

Qianqian Guo ◽

Xiaojie Lin ◽

Lingling Ye ◽

Rui Xu ◽

Yan Dai ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Meta Analysis ◽

Line Treatment ◽

Comparative Efficacy ◽

First Line ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18)

10.1158/1538-7445.am2014-ct101 ◽

2014 ◽

Cited By ~ 23

Author(s):

Richard S. Finn ◽

John P. Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M. Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00051-0 ◽

2015 ◽

Vol 16 (7) ◽

pp. 816-829 ◽

Cited By ~ 169

Author(s):

Sara A Hurvitz ◽

Fabrice Andre ◽

Zefei Jiang ◽

Zhimin Shao ◽

Max S Mano ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Multicentre Trial ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

First Line Treatment

Download Full-text

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC

Annals of Oncology ◽

10.1093/oxfordjournals.annonc.a010544 ◽

1996 ◽

Vol 7 (2) ◽

pp. 165-171 ◽

Cited By ~ 67

Author(s):

P. Fumoleau ◽

B. Chevallier ◽

P. Kerbrat ◽

Y. Krakowski ◽

J.-L. Misset ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Clinical Screening ◽

Multicentre Phase ◽

First Line Treatment

Download Full-text

Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women

European Journal of Cancer ◽

10.1016/s0959-8049(03)00602-6 ◽

2003 ◽

Vol 39 (16) ◽

pp. 2310-2317 ◽

Cited By ~ 65

Author(s):

B. Thürlimann ◽

J.F.R. Robertson ◽

J.M. Nabholtz ◽

A. Buzdar ◽

J. Bonneterre

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Pertuzumab for First-Line Treatment of HER2+ Advanced Breast Cancer: Where Does It Fit?

The Journal of OncoPathology ◽

10.13032/tjop.2052-5931.100082 ◽

2014 ◽

Vol 2 (2) ◽

pp. 25-31

Author(s):

Tadeusz Pie Kowski

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.614 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 614-614

Author(s):

L. Chow ◽

B. Xu ◽

L. Y. Dirix ◽

B. Moy ◽

E. Leip ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text